Systemic Lupus Erythematosus
Systemic lupus erythematosus (lupus) is an autoimmune
disease that results in episodes of inflammation in
joints, tendons, and other connective tissues and
organs.
Different tissues and organs become inflamed in
different people, and the severity of the disease ranges
from mild to debilitating, depending on the number and
variety of antibodies that appear and the organs
affected. About 90 percent of the people who have lupus
are young women in their late teens to 30s, but
children, mostly girls, and older men and women can also
be affected.
Occasionally, certain heart drugs (hydralazine,
procainamide, and beta-blockers) can cause a lupus-like
syndrome that disappears after the drug is discontinued.
Characteristics of Lupus
-
Facial rash
-
Skin rash
-
Sensitivity to sunlight
-
Mouth sores
-
Fluid around the lungs, heart, or other organs
-
Arthritis
-
Kidney dysfunction
-
Low white blood cell count or low platelet count
-
Nerve or brain dysfunction
-
Positive results of a blood test for antinuclear
antibodies, followed in some cases by positive
results of a more specific test for antibodies to
double-stranded DNA
-
Anemia
Symptoms
The number and variety of antibodies that can appear in
lupus are greater than those in any other disease, and
they--along with other unknown factors--determine which
symptoms develop. Therefore, symptoms, and their
severity and gravity, vary greatly from person to
person. Lupus can be quite mild, or it can be
devastating, disabling, or fatal. For example, in people
who have antibodies that affect only the skin, the skin
symptoms may be mild--protecting the skin from sunlight
may even prevent them--or they may be severe and
disfiguring.
Because symptoms vary greatly, lupus may resemble many
other diseases. For example, the connective tissue of
joints is commonly affected in lupus, and the arthritis
that results may resemble rheumatoid arthritis. Lupus
may resemble epilepsy or some psychologic disorders when
the brain is affected.
Although lupus can be chronic and ongoing, it usually
flares up intermittently. What triggers a flare-up of
lupus in people who are predisposed to it often isn't
known, although sunlight seems to be one factor.
Lupus may begin with a fever. A high fever can occur
abruptly, or episodes of fever and a generally sick
feeling (malaise) can come and go, sometimes for years.
About 90 percent of people with lupus have joint
inflammation, which ranges from intermittent mild aches
to severe arthritis in several joints. Years of joint
symptoms may precede other symptoms. In fact, many
people who have lupus recall having growing pains as
children. Long-standing joint inflammation can lead to
deformity and permanent damage to the joint and
surrounding tissue, but the bone doesn't erode as it
does in rheumatoid arthritis.
Skin rashes are common, often occurring on the face,
neck, upper chest, and elbows. The most characteristic
is a red, butterfly-shaped rash that appears across the
bridge of the nose and on the cheeks. Circular, raised
bumps may develop. These rashes rarely blister or become
raw. Mouth sores are also common. Mottled,
reddish-purple areas may appear on the sides of the
palms and on the fingers; swelling and redness may
develop around the nails. Hair loss is common when the
disease is active. In almost half the people who have
lupus, the skin is highly sensitive to light; it may
burn easily or a rash may develop after exposure to
sunlight.
Occasionally, an inflammation develops and extra fluid
accumulates in the membranes surrounding the lungs. This
inflammation (pleurisy) can make deep breathing painful.
Fluid may accumulate in the sac around the heart,
resulting in pericarditis, which can cause severe,
constant chest pain. Children, young adults, and blacks
with lupus commonly develop swollen lymph nodes
throughout the body, and about 10 percent of the people
with lupus develop an enlarged spleen.
Sometimes the nervous system is affected, causing
headaches, personality changes, seizures, and symptoms
that resemble dementia, such as difficulty in thinking
clearly. Strokes occur less often. Protein or red blood
cells in the urine, detected by a laboratory test,
indicate kidney damage caused by glomerulonephritis, an
inflammation of the kidneys, which is a common
consequence of lupus. If severe, progressive kidney
disease develops, blood pressure can become dangerously
high, and kidney failure, which may be fatal, can
follow. Early detection and treatment of kidney damage
in people who have lupus reduces the incidence of severe
kidney disease.
Diagnosis
Lupus is diagnosed mainly on the basis of its symptoms,
particularly if they occur in a young woman. Because of
the wide range of symptoms, distinguishing lupus from
similar diseases can be difficult at first.
Laboratory tests can help confirm the diagnosis. A blood
test can detect antinuclear antibodies, which are
present in almost all people who have lupus. However,
these antibodies also occur in other diseases.
Therefore, if antinuclear antibodies are detected, a
test for antibodies to double-stranded DNA is also
performed. A high level of these antibodies is almost
specific for lupus, but not all people who have lupus
have these antibodies. Blood tests to measure complement
levels (a group of proteins that are part of the immune
system) and to detect other antibodies may be performed
to predict the activity and course of the disease.
Kidney damage from lupus may be detected by blood and
urine tests. Sometimes a biopsy of kidney tissue must be
performed to help the doctor plan treatment.
Prognosis and Treatment
Because the course of lupus is unpredictable, the
prognosis varies widely. The disease tends to be chronic
and relapsing, often with symptom-free periods that can
last for years. Flare-ups rarely occur after menopause.
The prognosis has improved markedly over the last two
decades. Usually, if the initial inflammation is
controlled, the long-term prognosis is good.
If the symptoms of lupus are caused by taking a drug,
discontinuing the drug cures the lupus, although the
recovery may take months.
Treatment depends on which organs are affected and
whether the disease is mild or severe. Mild lupus is
characterized by fever, arthritis, rash, mild heart and
lung involvement, and headaches. Severe lupus may cause
life-threatening blood disorders, massive heart and lung
involvement, significant kidney damage, vasculitis of
the arms and legs or gastrointestinal tract, or severe
nervous system dysfunction.
Mild disease may require little or no treatment.
Nonsteroidal anti-inflammatory drugs (NSAIDs) often can
relieve joint pain. Aspirin is used in low doses if the
person's blood has a tendency to clot, as happens in
some people with lupus; doses that are too high can harm
the liver. Hydroxychloroquine, chloroquine, or
quinacrine, sometimes taken in combination, helps
relieve joint and skin symptoms.
Severe disease is treated immediately with a
corticosteroid such as prednisone. The dose and duration
of treatment depend on which organs are affected.
Sometimes an immunosuppressive drug such as azathioprine
or cyclophosphamide is given to suppress the body's
autoimmune attack. The combination of a corticosteroid
and an immunosuppressive drug is most often used for
severe kidney or nervous system disease and vasculitis.
Once the initial inflammation is controlled, a doctor
determines the dose that most effectively suppresses the
inflammation over the long term. Usually, the dose of
prednisone is gradually decreased when symptoms are
controlled and laboratory test results improve. Relapses
or flare-ups can occur during this process. For most
people who have lupus, the dose of prednisone can
eventually be decreased or discontinued.
Surgical procedures and pregnancy are more complicated
for people who have lupus, and they require close
medical supervision. Miscarriages and flare-ups after
childbirth are common.
Email This Page
Print
This Page
|
|
| |
NEWS & EVENTS
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
16.11.2005
MabThera – a unique approach providing lasting
benefits for patients with rheumatoid arthritis
Comprehensive long-term clinical success achieved in
difficult-to-treat patients following just two
administrations, two weeks apart
›
more
|
|
 |
| |
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
06.09.2005
Roche files first rheumatoid arthritis indication for
MabThera in Europe
MabThera: a medicine used to treat non-Hodgkin's
lymphoma
MabThera delivers significant and sustained relief from
symptoms in patients with difficult-to-treat rheumatoid
arthritis.
›
more
|
|
 |
| |
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
06.04.2005
MabThera significantly improves symptoms in patients
with rheumatoid arthritis who inadequately responded to
anti-TNFα therapies
Third large randomised trial to evaluate efficacy and
safety of MabThera in RA
Roche, Genentech and Biogen Idec announced today that
REFLEX1, a pivotal Phase III study of MabThera (rituximab), successfully met its
primary endpoint in the group of patients with the most difficult-to-treat
rheumatoid arthritis (RA).
›
more
|
|
 |
Legal Disclamer
|
Legal Disclaimer
Copyright
©WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune
Diseases.
This Web site was developed in 2005 as a service provided by the
WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune
Diseases. This Web site provides selected information available
about lupus and arthritis. It is important that public see a
healthcare professional for detailed information about medical
conditions and treatment. This information is not intended to be a
substitute for the advice of a healthcare professional, or a
recommendation for any particular treatment plan. The WHO-ILAR
COPCORD Stage II Education on Treatment of the Autoimmune Diseases
has made and will continue to make efforts to include accurate and
up-to-date information on this Web site.
If you have any
questions, please contact us:
Webmaster
Phone: 62-24-8447-345
Fax: 62-24-8310-028
admin@LupusArthritisIndonesia.org
|
|